Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington's disease is related to their physiological efficacy


ABSTRACT: Our aim was to find an effective treatment for the dysfunction in energy regulation and hypothalamic integrity occurring in many HuntingtonM-bM-^@M-^Ys disease (HD) patients and mouse models. HD is a neurodegenerative disease caused by an expanded CAG repeat and is characterized by mutant huntingtin aggregates, cell death, progressive motor impairment, and cognitive alterations. Changes in neuroendocrine function, body weight, energy metabolism, euglycemia, appetite function, sleep, and gut function can also occur. It is likely that the locus of these alterations is the hypothalamus. Male B6C3-Tg(HD82Gln)81Dbo/J (N171-82Q) mice and age-matched wild-type (WT) mice were used. Transgenic mice were identified by PCR analysis of tail DNA. N171-82Q mice express 82 polyglutamine repeats and display multiple HuntingtonM-bM-^@M-^Ys disease-like symptoms. Either Ex-4 (n=10, 300 M-BM-5L of 0.1 M-BM-5mol/L solution, Bachem, Torrance, CA), the GLP-1-transferrin hybrid molecule (n=10, GLP-1Tf, 1mg/kg), insulin (n=10, 5Units, Lantus) or a saline vehicle treatment (n=10, phosphate buffered saline, PBS; Sigma, St. Louis, MO) was administered by a once-daily subcutaneous injection. Injections were started when animals were pre-symptomatic (2 months of age) and continued for 5 weeks. 3 Mice from each treatment qroup were used for the microarray analysis. RNA was extracted from frozen hypothalamus tissue using 1.0mm glass beads (BioSpec Products, Inc.) in a Precellys 24 Tissue Homogenizer (Bertin Technologies) and Qiagen RNeasy Mini Kits according to manufacturer's specifications. Quality and quantity of the total RNA was checked with the Agilent 2100 bioanalyzer using RNA 6000 Nano chips. The standard Illumina protocol using Illumina TotalPrep RNA Amplification Kit (Ambion; Austin, TX, cat # IL1791) was used to biotin label the aRNA generated and then hybridized to Illumina's Sentrix MouseRef-8 v2 Expression BeadChips (Illumina, San Diego, CA). Arrays were scanned at a resolution of 0.8um using the Beadstation 500 X from Illumina.

ORGANISM(S): Mus musculus

SUBMITTER: Kevin Becker 

PROVIDER: E-GEOD-39586 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Martin Bronwen B   Chadwick Wayne W   Cong Wei-na WN   Pantaleo Nick N   Daimon Caitlin M CM   Golden Erin J EJ   Becker Kevin G KG   Wood William H WH   Carlson Olga D OD   Egan Josephine M JM   Maudsley Stuart S  

The Journal of biological chemistry 20120720 38


Our aim was to employ novel analytical methods to investigate the therapeutic treatment of the energy regulation dysfunction occurring in a Huntington disease (HD) mouse model. HD is a neurodegenerative disorder that is characterized by progressive motor impairment and cognitive alterations. Changes in neuroendocrine function, body weight, energy metabolism, euglycemia, appetite function, and gut function can also occur. It is likely that the locus of these alterations is the hypothalamus. We de  ...[more]

Similar Datasets

2008-08-14 | GSE1918 | GEO
2008-10-25 | E-GEOD-1918 | biostudies-arrayexpress
2015-12-31 | E-GEOD-63675 | biostudies-arrayexpress
2015-12-31 | GSE63675 | GEO
| PRJNA420847 | ENA
2014-02-26 | E-GEOD-55315 | biostudies-arrayexpress
2018-07-05 | GSE107613 | GEO
2024-10-17 | PXD054629 | Pride
2014-10-24 | E-GEOD-62639 | biostudies-arrayexpress
2018-04-24 | GSE108255 | GEO